Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development

Viruses. 2023 Mar 23;15(4):813. doi: 10.3390/v15040813.

Abstract

Lately, the global incidence of flavivirus infection has been increasing dramatically and presents formidable challenges for public health systems around the world. Most clinically significant flaviviruses are mosquito-borne, such as the four serotypes of dengue virus, Zika virus, West Nile virus, Japanese encephalitis virus and yellow fever virus. Until now, no effective antiflaviviral drugs are available to fight flaviviral infection; thus, a highly immunogenic vaccine would be the most effective weapon to control the diseases. In recent years, flavivirus vaccine research has made major breakthroughs with several vaccine candidates showing encouraging results in preclinical and clinical trials. This review summarizes the current advancement, safety, efficacy, advantages and disadvantages of vaccines against mosquito-borne flaviviruses posing significant threats to human health.

Keywords: flavivirus; mosquito-borne; vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Culicidae*
  • Dengue*
  • Flavivirus Infections*
  • Flavivirus*
  • Humans
  • Viral Vaccines*
  • Yellow Fever* / epidemiology
  • Zika Virus Infection* / prevention & control
  • Zika Virus*

Substances

  • Viral Vaccines

Grants and funding

This research received no external funding.